Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Public ClinicalTrials.gov record NCT00891839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Study identification
- NCT ID
- NCT00891839
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Cephalon
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- Bendamustine Drug
- Rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Nov 30, 2011
- Completion
- Apr 30, 2014
- Last update posted
- Nov 3, 2014
2009 – 2014
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 11 | Fountain Valley | California | — | — |
| Teva Investigational Site 2 | Los Angeles | California | — | — |
| Teva Investigational Site 35 | Orlando | Florida | — | — |
| Teva Investigational Site 30 | Lafayette | Indiana | — | — |
| Teva Investigational Site 20 | Bethesda | Maryland | — | — |
| Teva Investigational Site 4 | Hackensack | New Jersey | — | — |
| Teva Investigational Site 3 | Buffalo | New York | — | — |
| Teva Investigational Site 43 | Gettysburg | Pennsylvania | — | — |
| Teva Investigational Site 33 | Bryan | Texas | — | — |
| Teva Investigational Site 41 | Grapevine | Texas | — | — |
| Teva Investigational Site 23 | Lynchburg | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00891839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2014 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00891839 live on ClinicalTrials.gov.